RE: Investor presentation24 Oct 2025 08:44
Thorn Im afraid its you thats talking rubbish again. These 2 statements are from the RNs
Groundbreaking oncology development with the first dual payload peptide drug conjugate platform, establishing Avacta as a leader in combination therapy innovation"
"The development of the first dual payload peptide drug conjugate platform marks a major leap forward in oncology therapy. This significantly extends the potential of our innovative pre|CISION® platform by implementing combination cancer therapy in a single medicine."
Then you statement :-
I've read the RNS and appreciate that they think it's a good think, why better than the co-administration of two drugs simultaneously?